Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWarpaint London Regulatory News (W7L)

Share Price Information for Warpaint London (W7L)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 472.50
Bid: 470.00
Ask: 475.00
Change: -12.50 (-2.58%)
Spread: 5.00 (1.064%)
Open: 485.00
High: 485.00
Low: 472.50
Prev. Close: 485.00
W7L Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ward & Hagon Contract Renewal

1 Feb 2024 07:00

RNS Number : 6047B
Warpaint London PLC
01 February 2024
 

1 February 2024

 

Warpaint London PLC

("Warpaint", the "Company" or the "Group")

 

Ward & Hagon Contract Renewal

 

Warpaint London plc (AIM: W7L), the specialist supplier of colour cosmetics and owner of the W7 and Technic brands, announces that on 31 January 2024, it renewed its contract (the "Contract") with Ward & Hagon Management Consulting LLP ("Ward & Hagon") for a period of 24 months, effective 1 January 2024. At the end of the 24 month period, the Contract will continue on the same terms subject to a six month notice period which can be served by either party.

 

The Company originally appointed Ward & Hagon, a provider of practical business solutions, in February 2020 to assist it in implementing its strategic growth plan. The contract was renewed on 19 February 2021 for a period of 12 months and was again renewed on 1 March 2022 for a period of 24 months effective from 1 January 2022. The objective of the Contract renewal is to continue to accelerate Warpaint's growth and drive further business transformation.

 

The Contract has a total fixed value over 24 months of £450,000 (£225,000 per annum) and includes the services of Paul Hagon, an executive director of the Company and Martyn Ward, together with other members of the Ward & Hagon team. In addition, Ward & Hagon has an opportunity under the Contract to earn up to £175,000 per annum through non-discretionary performance related sales bonuses and commissions. Payments under the Contract will be satisfied from the Group's operating cash flows.

 

The Board is of the view that Ward & Hagon has been important to the Group's success over the last few years and the services provided under the Contract represent good value to shareholders.

 

 

Related Party Transaction

 

Paul Hagon, an executive director of Warpaint, is a member of Ward & Hagon. Accordingly the renewal of the Contract is classified as a related party transaction pursuant to the AIM Rules for Companies. The independent directors of the Company (being all executive and non-executive directors except Mr Hagon), having consulted with Shore Capital, the Company's Nominated Adviser, consider that the terms of the Contract renewal are fair and reasonable insofar as the Company's shareholders are concerned.

 

Enquiries:

Warpaint London

Sam Bazini - Chief Executive Officer

Eoin Macleod - Managing Director

Neil Rodol - Chief Financial Officer

 

c/o IFC

 

Shore Capital (Nomad and Broker)

Patrick Castle, Daniel Bush - Corporate Advisory

Fiona Conroy - Corporate Broking

 

 

020 7408 4090

IFC Advisory (Financial PR & IR)

Tim Metcalfe, Graham Herring, Florence Chandler

020 3934 6630

 

 

Warpaint London plc

 

Warpaint sells branded cosmetics under the lead brand names of W7 and Technic. W7 is sold in the UK primarily to retailers and internationally to local distributors or retail chains. The Technic brand is sold in the UK and continental Europe with a significant focus on the gifting market, principally for high street retailers and supermarkets. In addition, Warpaint supplies own brand white label cosmetics produced for several major high street retailers. The Group also sells cosmetics using its other brand names of Man'stuff, Body Collection, Very Vegan, and Chit Chat.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTEAPFFDFALEFA
Date   Source Headline
24th Apr 20247:00 amRNSResults for the year ended 31 December 2023
9th Apr 20247:00 amRNSBlock listing Interim Return
9th Apr 20247:00 amRNSTrading Update and Notice of Results
26th Mar 20242:37 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSWard & Hagon Contract Renewal
12th Jan 20247:00 amRNSTrading Update
12th Dec 20237:00 amRNSAppointment of Non-Executive Directors
1st Dec 20233:37 pmRNSTotal Voting Rights
24th Nov 20237:00 amRNSGrant of Options
21st Nov 202311:23 amRNSPDMR Dealing
20th Nov 20231:24 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSTrading Update
9th Nov 20237:00 amRNSBlock Listing Interim Return
31st Oct 20237:00 amRNSTotal Voting Rights
13th Oct 20233:38 pmRNSHolding(s) in Company
4th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20233:26 pmRNSHolding(s) in Company
3rd Oct 202312:25 pmRNSBlocklisting Application
28th Sep 20235:47 pmRNSHolding(s) in Company
20th Sep 20237:00 amRNSInterim Results
19th Sep 20233:51 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
22nd Aug 202312:31 pmRNSHolding(s) in Company
27th Jul 20234:34 pmRNSHolding(s) in Company
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20231:40 pmRNSResult of AGM
28th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSTrading Update
6th Jun 20237:00 amRNSPDMR Dealings
24th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
9th May 202311:28 amRNSHolding(s) in Company
2nd May 20234:31 pmRNSBlocklisting Application
26th Apr 20237:00 amRNSResults for the year ended 31 December 2022
24th Mar 20237:00 amRNSTrading Update and Notice of Results
14th Feb 202310:16 amRNSAIM Rule 17 Notification
11th Jan 20237:00 amRNSFull Year Trading Update
3rd Jan 20237:00 amRNSResignation of Non-Executive Director
14th Oct 20227:00 amRNSRenewal of New Moorcroft House lease at Silsden
21st Sep 20227:00 amRNSInterim Results
16th Sep 20227:00 amRNSChange of Adviser
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20222:06 pmRNSSecond Price Monitoring Extn
8th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 202211:05 amRNSSecond Price Monitoring Extn
8th Sep 202211:00 amRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSTrading Update
1st Sep 20227:00 amRNSNotice of Results and Investor Webinar
29th Jun 20227:00 amRNSPMDR / PCA Dealing
28th Jun 20227:00 amRNSDirector/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.